Summary of mentioned lipopeptide vaccine adjuvants

StructureName (abbreviation)SourceApplication
Pam3CSK4Modification of MALP-2 (Mycoplasma fermentas)Vaccine adjuvant, TLR1/TLR2 heterodimer agonist; tumor cytotoxicity [52]; used in various vaccines [5360]
Pam2CSK4Modification of MALP-2 (Mycoplasma fermentas)Vaccine adjuvant, TLR2/TLR6 heterodimer agonist; used in various vaccines [53, 58, 6163]; clinical trials: phase 1/2a in PUL-042, a prophylactic and therapeutic drug used against bacterial and viral pulmonary infections [64]
35dModifications of Pam2CSK4TLR2 agonist [65]
(2S,5S,8S,14R,18R)-2,5,8-tris(4-aminobutyl)-4,7,10,13,21-pentaoxo-14-palmitamido-18-[(tetradecylcarbamoyl)oxy]-20-oxa-16-thia-3,6,9,12,22-pentaazahexatriacontan-1-oic acid (SUP3)Modifications of Pam3CSK4Vaccine adjuvant (tumor model); TLR2 agonist [66]
R&S: 8a
R: 8b
S: 8c
Structure optimization of Pam2CSK4/Pam3CSK4 [67, 68]Vaccine adjuvant (influenza) [68]; TLR2/6 agonist
R&S: 9a
R: 9b
S: 9c
TLR2/6 agonist
R4Pam2CysBStructure optimization of Pam2CSK4/Pam3CSK4 [69]
Vaccine adjuvant [ovalbumin (OVA)]; TLR2 agonist [69]
Lipid core peptide (LCP)N/ATLR2, self-adjuvanting antigen carrier used against group A Streptococcus (GAS) infections [7072]
L1Conjugation of LCP to universal Th cell epitope P25 and GAS epitope J14Self-adjuvanting vaccine [70, 71]
lipoKALAN/AVaccine adjuvant used in combination with L1 to obtain J8-specific opsonizing antibodies upon vaccination [72, 73]
AG2-C16N/ASelf-adjuvanting vaccine carrier [bovine serum albumin (BSA)] [74]
PamadiFectinModification of Pam2CSK4TLR2/TLR7 agonist [75]
Fibroblast stimulating lipopeptide 1 (FSL-1)Streptococcus pyogenes (S. pyogenes)TLR2 agonist, vaccine adjuvant used against GAS [76]
Cyclic decapeptide carrier (CDC) and lipopeptide adjuvant KKSS-C16-C16-NH2N/AVaccine adjuvant system used against GAS [7779]
LP1Helicobacter pylori (H. pylori) adhesin ATLR2 agonist, vaccine adjuvant against H. pylori [80, 81]